Vazquez Ucha JC; Rodriguez D; Lasarte Monterrubio C; Lence E; Arca Suarez J; Maneiro M; Gato E; Perez A; Martinez Guitian M; Juan C; Oliver A; Bou G; Gonzalez Bello C; Beceiro A. 6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to beta-Lactam Antibiotics. Journal of Medicinal Chemistry. 2021. 64 (9): 6310-6328.
Gomez Zorrilla S; Becerra Aparicio F; Montesinos IL; de Gopegui ER; Grau I; Pintado V; Padilla B; Benito N; Boix Palop L; Farinas MC; Penaranda M; Gamallo MR; Martinez JA; Morte Romea E; Del Pozo JL; Duran Jorda X; Diaz Reganon J; Lopez Mendoza D; Canton R; Oliver A; Ruiz Garbajosa P; Horcajada JP. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. Infectious Diseases and Therapy. 2021. 10 (4): 2677-2699.
Santopolo G; Rojo Molinero E; Clemente A; Borges M; Oliver A; de la Rica R. Bedside Detection of Carbapenemase-Producing Pathogens with Plasmonic Nanosensors.Sensors and Actuators B-Chemical. 2021. 329.
Roman F; Mendez Echevarria A; Del Rosal T; Garcia Vera C; Escosa Garcia L; Agud M; Chaves F; Gutierrez Fernandez J; de Gopegui ER; Ruiz Carrascoso G; Ruiz Gallego MD; Bernet A; Quevedo SM; Fernandez Verdugo AM; Sainz T; Calvo C. Characterization of methicillin-resistant Staphylococcus aureus strains colonizing the nostrils of Spanish children. Microbiology Open. 2021. 10 (5).
Lang YZ; Shah NR; Tao X; Reeve SM; Zhou JQ; Moya B; Sayed A; Dharuman S; Oyer JL; Copik AJ; Fleischer BA; Shin E; Werkman C; Basso KB; Lucas DD; Sutaria DS; Megroz M; Kim TH; Loudon Hossler V; Wright A; Jimenez Nieves RH; Wallace MJ; Cadet KC; Jiao YY; Boyce JD; LoVullo ED; Schweizer HP; Bonomo RA; Bharatham N; Tsuji BT; Landersdorfer CB; Norris MH; Shin BS; Louie A; Balasubramanian V; Lee RE; Drusano GL; Bulitta JB. Combating multidrug-resistant bacteria by integrating a novel target site penetration and receptor binding assay platform into translational modeling. Clinical Pharmacology & Therapeutics. 2021. 109 (4): 1000-1020.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; MacGowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez Bano J; Morales I; Oliver A; Ruiz de Gopegui E; Cano A; Machuca I; Gozalo Marguello M; Martinez LM; Gonzalez Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici
L; Yahav D. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. Journal of Antimicrobial Chemotherapy. 2021. 76 (8): 2172-2181.
Reina J; Suarez L; Lara P. Detection of respiratory viruses in patients with suspected SARS-CoV-2 infection. Enfermedades Infecciosas y Microbiologia Clinica. 2021. 39 (1): 52-53.
Hernandez Garcia M; Garcia Castillo M; Garcia Fernandez S; Melo Cristino J; Pinto MF; Goncalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Bou G; Cercenado E; Delgado Valverde M; Oliver A; Pitart C; Rodriguez Lozano J; Tormo N; Romano J; Passaro L; Paixao L; Lopez Mendoza D; Diaz Reganon J; Canton R; STEP Study GRP; SUPER Study GRP. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS. Journal of Antimicrobial Chemotherapy. 2021. 76 (2): 370-379.
Gomis Font MA; Pitart C; del Barrio Tofino E; Zboromyrska Y; Cortes Lara S; Mulet X; Marco F; Vila J; Lopez Causape C; Oliver A. Emergence of Resistance to Novel Cephalosporin-beta-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump. Antimicrobial Agents and Chemotherapy. 2021. 65 (8).
Buades J; Losada I; Gonzalez Moreno J; Penaranda M; Vilaplana L; Roda N; Rey A; Rodriguez A; Garau M; de Gopegui ER; Serra A; Saurina J; Payeras A. Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old. Vaccines. 2021. 9 (2).
Sayed A; Shah NR; Basso KB; Kamat M; Jiao YY; Moya B; Sutaria DS; Lang YZ; Tao X; Liu WG; Shin E; Zhou JQ; Werkman C; Louie A; Drusano GL; Bulitta JB. First Penicillin-Binding Protein Occupancy Patterns for 15 beta-Lactams and beta-Lactamase Inhibitors in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2021. 65 (1).
Clemente A; Alba Patino A; Santopolo G; Rojo Molinero E; Oliver A; Borges M; Aranda M; del Castillo A; de la Rica R. Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic Liquefaction of Respiratory Samples from COVID-19 Patients. Analytical Chemistry. 2021. 93 (12): 5259-5266.
Montero MM; Domene Ochoa S; Lopez Causape C; Luque S; Sorli L; Campillo N; Padilla E; Prim N; Ferrer Alapont L; Angulo Brunet A; Grau S; Oliver A; Horcajada JP. Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Scientific Reports. 2021. 11 (1): 22178-22178.
Barcelo I; Cabot G; Palwe S; Joshi P; Takalkar S; Periasamy H; Cortes Lara S; Zamorano L; Sanchez Diener I; Moya B; Bhagwat S; Patel M; Oliver A. In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy. Journal of Antimicrobial Chemotherapy. 2021. 76 (10): 2546-2557.
Fraile Ribot PA; Fernandez J; Gomis Font MA; Forcelledo L; Mulet X; Lopez Causape C; Oliver A. In Vivo Evolution of GES beta-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections. Antimicrobial Agents and Chemotherapy. 2021. 65 (9).
Arcos SC; Lira F; Robertson L; Gonzalez MR; Carballeda Sangiao N; Sanchez Alonso I; Zamorano L; Careche M; Jimenez Ruiz Y; Ramos R; Llorens C; Gonzalez Munoz M; Oliver A; Martinez JL; Navas A. Metagenomics Analysis Reveals an Extraordinary Inner Bacterial Diversity in Anisakids (Nematoda: Anisakidae) L3 Larvae. Microorganisms. 2021. 9 (5).
Lopez Arguello S; Montaner M; Oliver A; Moya B. Molecular Basis of AmpC beta-Lactamase Induction by Avibactam in Pseudomonas aeruginosa: PBP Occupancy, Live Cell Binding Dynamics and Impact on Resistant Clinical Isolates Harboring PDC-X Variants. International Journal of Molecular Sciences. 2021. 22 (6).
Arca Suarez J; Lasarte Monterrubio C; Rodino Janeiro BK; Cabot G; Vazquez Ucha JC; Rodriguez Iglesias M; Galan Sanchez F; Beceiro A; Gonzalez Bello C; Oliver A; Bou G. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections. Journal of Antimicrobial Chemotherapy. 2021. 76 (1): 91-100.
Domenech Sanchez A; Laso E; Genestar E; Berrocal CI. Norovirus outbreak causing gastroenteritis in a hotel in Menorca, Spain. Enfermedades Infecciosas y Microbiologia Clinica. 2021. 39 (1): 22-24.
Clemente A; Alba Patino A; Santopolo G; Baron E; Rojo Molinero E; Oliver A; Perez Barcena J; de Cos PM; Aranda M; del Castillo A; Socias A; Borges M; de la Rica R. Optimized detection of lung IL-6 via enzymatic liquefaction of low respiratory tract samples: application for managing ventilated patients. Analyst. 2021. 146 (21): 6537-6546.
Bulilete O; Lorente P; Leiva A; Carandell E; Oliver A; Rojo E; Pericas P; Llobera J; COVID 19 Primary Care Research G. Panbio (TM) rapid antigen test for SARSCoV-2 has acceptable accuracy in symptomatic patients in primary health care. Journal of Infection. 2021. 82 (3): 391-398.
Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Journal of Global Antimicrobial Resistance. 2021. 2655-63.
Khorrami Minaei S; Garrido Durán C; García Hernández M; García Amengual I; Mena Ribas A. Poor agreement between clinical screening and universal pre-procedure SARS-CoV-2 PCR testing prior to endoscopy. Revista Espanola de Enfermedades Digestivas. 2021. 113 (9): 649-655.
Cortes Lara S; Barrio Tofiño ED; López Causapé C; Oliver A; GEMARA SEIMC/REIPI Pseudomonas study G; Martínez L; Bou G; Zamorano L; Sánchez Diener I; Galán F; Gracia I; Rodríguez MA; Martín L; Sánchez JM; Viñuela L; García MV; Lepe JA; Aznar J; López Hernández I; Seral C; Castillo García FJ; López Calleja AI; Aspiroz C; Iglesia P; Ramón S; Riera E; Pérez MC; Gallegos C; Calvo J; Quesada MD; Pitart C; Marco F; Hoyos Y; Horcajada JP; Larrosa N; González JJ; Tubau F; Capilla S; Pérez Moreno MO; Centelles MJ; Padilla E; Rivera A; Mirelis B; Rodríguez Tarazona RE; Arenal Andrés N; Ortega MDP; Megías G; García I; Colmenarejo C; González JC; Martínez NM; Gomila B; Giner S; Tormo N; Garduño E; Agulla JA; Seoane A; Pita J; Vidal IP; Guzmán DM; García M; Pérez Del Molino ML; Barbeito G; Artiles F; Azcona Gutiérrez JM; Sáenz Y; Oteo JA; González A; Villa J; Chaves F; Cercenado E; Alarcón T; Zurita ND; Gijón D; Merino I; Morosini MI; Cantón R; Sánchez MI; Moreno L; Yagüe G; Leiva J; Barrios JL; Canut A; Oteo J. Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis. Clinical Microbiology and Infection. 2021. 27 (11):1631-1637.
Garcia Gasalla M; Ferrer JM; Fraile Ribot PA; Ferre Beltran A; Rodriguez A; Martinez Pomar N; Ramon Clar L; Iglesias A; Losada Lopez I; Fanjul F; Pou JA; Llompart Alabern I; Toledo N; Pons J; Oliver A; Riera M; Murillas J. Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission. Canadian Journal of Infectious Diseases & Medical Microbiology. 2021.
Causape CL; Candelas FG; Carmona MT; Palomo AO. Procedures in Clinical Microbiology (number 71, 2nd edition 2021). Enfermedades Infecciosas y Microbiologia Clinica. 2021. 39 (7):368-368.
Valero A; Rodriguez Gascon A; Isla A; Barrasa H; del Barrio Tofino E; Oliver A; Canut A; Solinis MA. Pseudomonas aeruginosa & nbsp; Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis. Pharmaceutics. 2021. 13 (11).
Pelegrin AC; Palmieri M; Mirande C; Oliver A; Moons P; Goossens H; van Belkum A. Pseudomonas aeruginosa: a clinical and genomics update. Fems Microbiology Reviews. 2021. 45 (6).
Wheatley R; Caballero JD; Kapel N; de Winter FHR; Jangir P; Quinn A; del Barrio Tofino E; Lopez Causape C; Hedge J; Torrens G; Van der Schalk T; Xavier BB; Fernandez Cuenca F; Arenzana A; Recanatini C; Timbermont L; Sifakis F; Ruzin A; Ali O; Lammens C; Goossens H; Kluytmans J; Kumar Singh S; Oliver A; Malhotra Kumar S; MacLean C. Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection. Nature Communications. 2021. 12 (1).
Hodcroft EB; Zuber M; Nadeau S; Vaughan TG; Crawford KHD; Althaus CL; Reichmuth ML; Bowen JE; Walls AC; Corti D; Bloom JD; Veesler D; Mateo D; Hernando A; Comas I; González Candelas F; SeqCOVID SPAIN C; [Oliver A; López Causapé C]. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature. 2021. 595 (7869): 707-712.
Torres A; Motos A; Riera J; Fernandez Barat L; Ceccato A; Perez Arnal R; Garcia Gasulla D; Penuelas O; Lorente JA; Rodriguez A; de Gonzalo Calvol D; Almansa R; Gabarrus A; Menendez R; Bermejo Martin JF; Ferrer R; Villar RA; Anon JM; Barbera C; Barberan J; Ortiz AB; Bustamante Munguira E; Caballero J; Carbajales C; Carbonell N; Catalan Gonzalez M; Galban C; Gumucio Sanguino VD; de la Torre MD; Diaz E; Estella A; Gallego E; Garmendia JLG; Garnacho Montero J; Gomez JM; Huerta A; Garcia RNJ; Loza Vazquez A; Marin Corral J; de la Gandara AM; Varela IM; Messa JL; Albaiceta GM; Novo MA; Penasco Y; Pozo Laderas JC; Ricart P; Salvador Ade I; Sanchez Miralles A; chinesta SS; Socias L; Sole Violan J; Sipmann FS; Lomas LT; Trenado J; Barbe F; CIBERESUCICOVID Project Cov20 0011; I. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. Critical Care. 2021. 25 (1).
Lopez MG; Chiner Oms A; de Viedma DG; Ruiz Rodriguez P; Bracho MA; Cancino Munoz I; D’Auria G; de Marco G; Garcia Gonzalez N; Goig GA; Gomez Navarro I; Jimenez Serrano S et al; SeqCOVID Spain C [Lopez Causape C]. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nature Genetics. 2021. 53 (10): 1405.
Montero MM; Domene Ochoa S; Lopez Causape C; Luque S; Sorli L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo Brunet A; Grau S; Oliver A; Horcajada JP. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Microbiology Spectrum. 2021. 9 (1).
Reina J; Duenas J; Fraile P. Use of dried blood from the heel (Guthrie card) in the diagnosis of congenital enterovirus infection. Anales de Pediatria. 2021. 94 (2): 114-115.
Gomila RM; Martorell G; Fraile Ribot PA; Domenech Sanchez A; Alberti M; Oliver A; Garcia Gasalla M; Alberti S. Use of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Analysis of Serum Peptidome to Classify and Predict Coronavirus Disease 2019 Severity. Open Forum Infectious Diseases. 2021. 8 (6).
Mulet X; Fernandez Esgueva M; Norte C; Zamorano L; del Barrio Tofino E; Oliver A; GEMARA SEIMC REIPI Pseudomonas study G. Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enfermedades Infecciosas y Microbiologia Clinica. 2021. 39 (6):279-282.
Cabot G; Lara Esbri P; Mulet X; Oliver A. Whole-genome sequence-guided PCR for the rapid identification of the Pseudomonas aeruginosa ST175 high-risk clone directly from clinical samples. Journal of Antimicrobial Chemotherapy.2021. 76 (4): 945-949.
Lopez Causape C; Fraile Ribot PA; Jimenez Serrano S; Cabot G; del Barrio Tofino E; Prado MC; Linares JM; Lopez A; Hurtado A; Riera E; Serra A; Rosello E; Carbo L; Fernandez Baca MV; Gallegos C; Saurina J; Arteaga E; Salom MM; Salva A; Nicolau A; Gonzalez Candelas F; Comas I; Oliver A. A Genomic Snapshot of the SARSCoV-2 Pandemic in the Balearic Islands. Frontiers in Microbiology. 2022. 12.
Gomila I; Socias A; Socias L; Gutierrez L; Ripoll T; Alarcón FJ; García AB; BARCELO B. Cardiac arrest following unsuspected self-poisoning with doxylamine. Therapeutic Drug Monitoring. 2022. 44 (2): 354-356.
Vidal Cortes P; Martin Loeches I; Rodriguez A; Bou G; Canton R; Diaz E; De la Fuente C; Torre Cisneros J; Nuvials FX; Salavert M; Aguilar G; Nieto M; Ramirez P; Borges M; Soriano C; Ferrer R; Maseda E; Zaragoza R. Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults. Antibiotics-Basel. 2022. 11 (9).
Vaquer A; Baron E; de la Rica R. Dissolvable Polymer Valves for Sweat Chrono-Sampling in Wearable Paper-Based Analytical Devices. ACS Sensors. 2022. 7 (2): 488-494.
Borges Sa M; Salaverria I; Cabas AC. Fluid therapy in sepsis and septic shock. Medicina Intensiva. 2022. 4614-25.
Claverias L; Daniel X; Martin Loeches I; Vidal Cortez P; Gomez Bertomeu F; Trefler S; Zaragoza R; Borges Sa M; Reyes LF; Quindos G; Peman J; Bodi M; Diaz E; Sarvise C; Pico E; Papiol E; Sole Violan J; Marin Corral J; Guardiola JJ; Rodriguez A; GETGAG SEMICYUC Working GRP. Impact of Aspergillus spp. isolation in the first 24 hours of admission in critically ill patients with severe influenza virus pneumonia. Medicina Intensiva. 2022. 46 (8): 426-435.
Santopolo G; Clemente A; Rojo Molinero E; Fernández S; Álvarez MC; Oliver A; de la Rica R. Improved cytometric analysis of untouched lung leukocytes by enzymatic liquefaction of sputum samples. Biological Procedures Online. 2022. 24 (1):17-17.
Russell SM; Alba Patino A; Vaquer A; Clemente A; de la Rica R. Improving the Quantification of Colorimetric Signals in Paper-Based Immunosensors with an Open-Source Reader. Sensors. 2022. 22 (5).
Alba Patino A; Vaquer A; Baron E; Russell SM; Borges M; de la Rica R. Micro- and nanosensors for detecting blood pathogens and biomarkers at different points of sepsis care. Microchimica Acta. 2022. 189 (2): 74-74.
Socias Crespí L; Gomila Muñiz I; Socias Mir A; Ripoll Vera T; Elorza Guerrero MÁ; Barceló Martín B. Monitoring free digoxin serum concentrations after injection of digoxin-specific antibody fragments in a man with chronic digoxin poisoning. Emergencias. 2022. 34 (3): 238-239.
Santopolo G; Clemente A; González Freire M; Russell SM; Vaquer A; Barón E; Aranda M; Socias A; del Castillo A; Borges M; de la Rica R. Plasma-induced nanoparticle aggregation for stratifying COVID-19 patients according to disease severity. Sensors and Actuators B-Chemical. 2022. 373132638-132638.
del Campo MMG; Vaquer A; de la Rica R. Polymer Components for Paper-Based Analytical Devices. Advanced Materials Technologies. 2022. 7 (8).
Santopolo G; Clemente A; Rojo Molinero E; Oliver A; Noe C; De la Rica R. Rapid Identification and Classification of Pathogens That Produce Carbapenemases and Cephalosporinases with a Colorimetric Paper-Based Multisensor. Analytical Chemistry. 2022. 94 (26): 9442-9449.
Vidal Cortes P; Santos ED; Alonso EA; Menendez RA; Ballesteros MA; Bodi MA; Laguna MLB; Montero JG; Sanchez MG; Sanchez ML; Martin Loeches I; Calvo AO; Galleymore PR; Carmona SA; Ojeda DA; Arebalo OB; Gonzalez HB; Sa MB; Castellanos Ortega A; Estella A; Roca RF; Gutierrez VF; Cabanes MF; Vich C; Iglesias CG; Hernandez Tejedor A; Cano J; Posadilla DI; Rivera JJJ; Jorge CL; Llompart Pou JA; Camps VL; Cardenas CL; Neira PM; Delgado MCM; Gonzalez MMM; Villen LM; Casals XN; Suner AO; Diaz MQ; Sedes PR; Nunez MR; Carbajo LD; Aguirregabiria MR; Oviedo AR; Betolaza IS; Cuesta CS; Canas BS; Ching CV; Gonzalez AV; Fenor LZ; Crespo RZ. Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units. Medicina Intensiva. 2022. 46 (2): 81-89.
Bargay Lleonart J; Sarubbo F; Arrizabalaga M; Guerra JM; Borras J; El Haji K; Flexas M; Perales J; Fernandez Baca V; Gallegos C; Cruz MR; Velasco S; Lopez V; Cruz A; Bautista Gili A; Jimenez Marco T; Girona Llobera E; Vilaplana L; Calonge L; Tena J; Galan MP; Payeras A. Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial. Journal of Clinical Medicine. 2022. 11 (11).
Atamna A, Margalit I, Ayada G, Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Fattah MA, Haquin J, Macgowan A, Chazan B, Yanovskay A, Ami RB, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Rodríguez-Baño J, de Cueto M, Oliver A, de Gopegui ER, Cano A, Machuca I, Gozalo-Marguello M, Martinez-Martinez L, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstei Y, Yahav D; ESCMID study group for infections in elderly (ESGIE). Outcomes of octogenarians and nonactogenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study. Infection. 2022 Dec 26. doi: 10.1007/s15010-022-01973-x. Online ahead of print. PMID: 3657167
Hernando-Amado S, López-Causapé C, Laborda P, Sanz-García F, Oliver A, Martínez JL. Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds. Microbiol Spectr. 2022 Dec 19:e0227622. doi: 10.1128/spectrum.02276-22. Online ahead of print. PMID: 36533961
Montaner M, Lopez-Argüello S, Oliver A, Moya B. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. Microbiol Spectr. 2022 Dec 8:e0303822. doi: 10.1128/spectrum.03038-22. Online ahead of print. PMID: 36475840
López-Causapé C, Maruri-Aransolo A, Gomis-Font MA, Penev I, Castillo MG, Mulet X, de Dios Caballero J, Campo RD, Cantón R, Oliver A. Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect. 2022 Nov 24:S1198-743X(22)00586-9. doi: 10.1016/j.cmi.2022.11.014. PMID: 36435424
Wheatley RM, Caballero JD, van der Schalk TE, De Winter FHR, Shaw LP, Kapel N, Recanatini C, Timbermont L, Kluytmans J, Esser M, Lacoma A, Prat-Aymerich C, Oliver A, Kumar-Singh S, Malhotra-Kumar S, Craig MacLean R. Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient. Nat Commun. 2022 Nov 22;13(1):6523. doi: 10.1038/s41467-022-34101-2. PMID: 36414617
Chastre J, François B, Bourgeois M, Komnos A, Ferrer R, Rahav G, De Schryver N, Lepape A, Koksal I, Luyt CE, Sánchez-García M, Torres A, Eggimann P, Koulenti D, Holland TL, Ali O, Shoemaker K, Ren P, Sauser J, Ruzin A, Tabor DE, Akhgar A, Wu Y, Jiang Y, DiGiandomenico A, Colbert S, Vandamme D, Coenjaerts F, Malhotra-Kumar S, Timbermont L, Oliver A, Barraud O, Bellamy T, Bonten M, Goossens H, Reisner C, Esser MT, Jafri HS; COMBACTE-MAGNET EVADE Study Group. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355. doi: 10.1186/s13054-022-04204-9. PMID: 36380312
Lopez-Montesinos I, Montero MM, Domene-Ochoa S, López-Causapé C, Echeverria D, Sorlí L, Campillo N, Luque S, Padilla E, Prim N, Grau S, Oliver A, Horcajada JP. Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa: In Vivo and In Vitro Evidence. Antibiotics (Basel). 2022 Oct 22;11(11):1456. doi: 10.3390/antibiotics11111456. PMID: 36358110
Barceló IM, Jordana-Lluch E, Escobar-Salom M, Torrens G, Fraile-Ribot PA, Cabot G, Mulet X, Zamorano L, Juan C, Oliver A. Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa. Microbiol Spectr. 2022 Oct 26;10(5):e0270022. doi: 10.1128/spectrum.02700-22. PMID: 36214681
Herrera-Espejo S, Del Barrio-Tofiño E, Cebrero-Cangueiro T, López-Causapé C, Álvarez-Marín R, Cisneros JM, Pachón J, Oliver A, Pachón-Ibáñez ME. Carbapenem Combinations for Infections Caused by Carbapenemase-Producing Pseudomonas aeruginosa: Experimental In Vitro and In Vivo Analysis. Antibiotics (Basel). 2022 Sep 7;11(9):1212. doi:10.3390/antibiotics11091212. PMID: 36139991
Hernández-García M, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Cruz H, Chaves C, Bou G, Cercenado E, Delgado-Valverde M, Oliver A, Pitart C, Rodríguez-Lozano J, Tormo N, Díaz-Regañón J, Pássaro L, Duarte J, Cantón R; STEP and SUPERIOR study groups. In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies). J Antimicrob Chemother. 2022 Oct 28;77(11):3163-3172. doi: 10.1093/jac/dkac298. PMID:36059128
Hernández-García M, García-Castillo M, Bou G, Cercenado E, Delgado-Valverde M, Oliver A, Pitart C, Rodríguez-Lozano J, Tormo N, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V, Vieira AR, Ramalheira E, Sancho L, Diogo J, Ferreira R, Cruz H, Chaves C, Duarte J, Pássaro L, Díaz-Regañón J, Cantón R. Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies). Microbiol Spectr. 2022 Oct 26;10(5):e0292722. doi:10.1128/spectrum.02927-22. Epub 2022 Aug 31. PMID: 36043877
Santos AL, van Venrooy A, Reed AK, Wyderka AM, García-López V, Alemany LB, Oliver A, Tegos GP, Tour JM. Hemithioindigo-Based Visible Light-Activated Molecular Machines Kill Bacteria by Oxidative Damage. Adv Sci (Weinh). 2022 Oct;9(30):e2203242. doi:10.1002/advs.202203242. PMID: 36002317
Sanz-García F, Hernando-Amado S, López-Causapé C, Oliver A, Martínez JL. Low Ciprofloxacin Concentrations Select Multidrug-Resistant Mutants Overproducing Efflux Pumps in Clinical Isolates of Pseudomonas aeruginosa. Microbiol Spectr. 2022 Oct 26;10(5):e0072322. doi: 10.1128/spectrum.00723-22. PMID: 36000896
Gual-de-Torrella A, Delgado-Valverde M, Pérez-Palacios P, Oteo-Iglesias J, Rojo-Molinero E, Macià MD, Oliver A, Pascual Á, Fernández-Cuenca F. Prevalence of the fimbrial operon mrkABCD, mrkA expression, biofilm formation and effect of biocides on biofilm formation in carbapenemase-producing Klebsiella pneumoniae isolates belonging or not belonging to high-risk clones. Int J Antimicrob Agents. 2022 Oct;60(4):106663. doi:10.1016/j.ijantimicag.2022.106663. PMID: 35995073
Lasarte-Monterrubio C, Fraile-Ribot PA, Vázquez-Ucha JC, Cabot G, Guijarro-Sánchez P, Alonso-García I, Rumbo-Feal S, Galán-Sánchez F, Beceiro A, Arca-Suárez J, Oliver A, Bou G. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2022 Sep 30;77(10):2809-2815. doi:10.1093/jac/dkac241. PMID: 35904000
Cerón-Pisa N, Shafiek H, Martín-Medina A, Verdú J, Jordana-Lluch E, Escobar-Salom M, Barceló IM, López-Causapé C, Oliver A, Juan C, Iglesias A, Cosío BG. Effects of Inhaled Corticosteroids on the Innate Immunological Response to Pseudomonas aeruginosa Infection in Patients with COPD. Int J Mol Sci. 2022 Jul 23;23(15):8127. doi:10.3390/ijms23158127. PMID: 35897707
Puig-Collderram B, Domene-Ochoa S, Salvà-Comas M, Montero MM, Duran X, González JR, Grau S, Oliver A, Horcajada JP, Padilla E, Segura C, Prim N. ATP Bioluminescence Assay To Evaluate Antibiotic Combinations against Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa. Microbiol Spectr. 2022 Aug 31;10(4):e0065122. doi:10.1128/spectrum.00651-22. PMID: 35876574
Gill CM, Oliver A, Fraile-Ribot PA, Nicolau DP. In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa. J Antimicrob Chemother. 2022 Sep 30;77(10):2803-2808. doi:10.1093/jac/dkac232. PMID: 35848936
Cañada-García JE, Moure Z, Sola-Campoy PJ, Delgado-Valverde M, Cano ME, Gijón D, González M, Gracia-Ahufinger I, Larrosa N, Mulet X, Pitart C, Rivera A, Bou G, Calvo J, Cantón R, González-López JJ, Martínez-Martínez L, Navarro F, Oliver A, Palacios-Baena ZR, Pascual Á, Ruiz-Carrascoso G, Vila J, Aracil B, Pérez-Vázquez M, Oteo-Iglesias J; GEMARA/GEIRAS-SEIMC/REIPI CARB-ES-19 Study Group. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Front Microbiol. 2022 Jun 30;13:918362. doi:10.3389/fmicb.2022.918362. PMID: 35847090
Santopolo G, Clemente A, Rojo-Molinero E, Oliver A, Noé C, de la Rica R. Rapid Identification and Classification of Pathogens That Produce Carbapenemases and Cephalosporinases with a Colorimetric Paper-Based Multisensor. Anal Chem. 2022 Jul 5;94(26):9442-9449. doi: 10.1021/acs.analchem.2c01724. PMID: 35748103
Montero MM, Domene-Ochoa S, López-Causapé C, López-Montesinos I, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Ferrer Alapont L, Grau S, Oliver A, Horcajada JP. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates. Microbiol Spectr. 2022 Jun 29;10(3):e0089222. doi: 10.1128/spectrum.00892-22. PMID: 35695526
Santos AL, Liu D, Reed AK, Wyderka AM, van Venrooy A, Li JT, Li VD, Misiura M, Samoylova O, Beckham JL, Ayala-Orozco C, Kolomeisky AB, Alemany LB, Oliver A, Tegos GP, Tour JM. Light-activated molecular machines are fast-acting broad-spectrum antibacterials that target the membrane. Sci Adv. 2022 Jun 3;8(22):eabm2055. doi:10.1126/sciadv.abm2055. PMID: 35648847
Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Fattah MA, Haquin J, Macgowan A, Grier S, Chazan B, Yanovskay A, Ami RB, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Rodríguez-Baño J, de Cueto M, Oliver A, de Gopegui ER, Cano A, Machuca I, Gozalo-Marguello M, Martinez-Martinez L, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study. Infect Dis Ther. 2022 Aug;11(4):1505-1519. doi: 10.1007/s40121-022-00657-1. PMID: 35612693
Torrens G, van der Schalk TE, Cortes-Lara S, Timbermont L, Del Barrio-Tofiño E, Xavier BB, Zamorano L, Lammens C, Ali O, Ruzin A, Goossens H, Kumar-Singh S, Kluytmans J, Paling F, MacLean RC, Köhler T, López-Causapé C, Malhotra-Kumar S, Oliver A; ASPIREICU study team. Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial. J Antimicrob Chemother. 2022 Jun 29;77(7):1862-1872. doi: 10.1093/jac/dkac122. PMID: 35451008
Alcoceba E, Gómez A, Lara-Esbrí P, Oliver A, Beltrán AF, Ayestarán I, Muñoz P, Escribano P, Guinea J. Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132FERG11 gene substitution in Spain. Clin Microbiol Infect. 2022 Aug;28(8):1113-1119. doi:10.1016/j.cmi.2022.02.025. PMID: 35439634
Barceló IM, Torrens G, Escobar-Salom M, Jordana-Lluch E, Capó-Bauzá MM, Ramón-Pallín C, García-Cuaresma D, Fraile-Ribot PA, Mulet X, Oliver A, Juan C. Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired β-Lactamases on Pseudomonas aeruginosa Virulence. Microbiol Spectr. 2022 Feb 23;10(1):e0201921. doi:10.1128/spectrum.02019-21. PMID: 35171032
Gato E, Anantharajah A, Arroyo MJ, Artacho MJ, Caballero JD, Candela A, Chudějová K, Constanso IP, Elías C, Fernández J, Jiménez J, Lumbreras P, Méndez G, Mulet X, Pérez-Palacios P, Rodríguez-Sánchez B, Cantón R, Hrabák J, Mancera L, Martínez-Martínez L, Oliver A, Pascual Á, Verroken A, Bou G, Oviaño M. Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software. Front Microbiol. 2022 Jan 27;12:789731. doi: 10.3389/fmicb.2021.789731. PMID: 35154029
Mateu-Borrás M, Zamorano L, González-Alsina A, Sánchez-Diener I, Doménech-Sánchez A, Oliver A, Albertí S. Molecular Analysis of the Contribution of Alkaline Protease A and Elastase B to the Virulence of Pseudomonas aeruginosa Bloodstream Infections. Front Cell Infect Microbiol. 2022 Jan 12;11:816356. doi: 10.3389/fcimb.2021.816356. PMID: 35145924
López-Causapé C, Fraile-Ribot PA, Jiménez-Serrano S, Cabot G, Del Barrio-Tofiño E, Prado MC, Linares JM, López A, Hurtado A, Riera E, Serra A, Roselló E, Carbó L, Fernández-Baca MV, Gallegos C, Saurina J, Arteaga E, Salom MM, Salvá A, Nicolau A, González-Candelas F, Comas I, Oliver A. A Genomic Snapshot of the SARS-CoV-2 Pandemic in the Balearic Islands. Front Microbiol. 2022 Jan 12;12:803827. doi:10.3389/fmicb.2021.803827. PMID: 35095814
Gomis-Font MA, Cabot G, López-Argüello S, Zamorano L, Juan C, Moyá B, Oliver A. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. J Antimicrob Chemother. 2022 Mar 31;77(4):957-968. doi: 10.1093/jac/dkab496. PMID: 35084040
Escobar-Salom M, Torrens G, Jordana-Lluch E, Oliver A, Juan C. Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives. Biol Rev Camb Philos Soc. 2022 Jun;97(3):1005-1037. doi: 10.1111/brv.12830. PMID: 35043558
Bilal H, Tait JR, Lang Y, Zhou J, Bergen PJ, Peleg AY, Bulitta JB, Oliver A, Nation RL, Landersdorfer CB. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0220321. doi: 10.1128/aac.02203-21. PMID: 35041509
Ruedas-López A, Alonso-García I, Lasarte-Monterrubio C, Guijarro-Sánchez P, Gato E, Vázquez-Ucha JC, Vallejo JA, Fraile-Ribot PA, Fernández-Pérez B, Velasco D, Gutiérrez-Urbón JM, Oviaño M, Beceiro A, González-Bello C, Oliver A, Arca-Suárez J, Bou G. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. doi: 10.1128/AAC.02067-21. PMID: 34930034
Pomar CA, Bonet ML, Ferre-Beltrán A, Fraile-Ribot PA, García-Gasalla M, Riera M, Picó C, Palou A. Increased mRNA Levels of ADAM17, IFITM3, and IFNE in Peripheral Blood Cells Are Present in Patients with Obesity and May Predict Severe COVID-19 Evolution. Biomedicines. 2022 Aug 18;10(8):2007. doi: 10.3390/biomedicines10082007. PMID: 36009555
Grimalt JO, Vílchez H, Fraile-Ribot PA, Marco E, Campins A, Orfila J, van Drooge BL, Fanjul F.Spread of SARS-CoV-2 in hospital areas. Environ Res. 2022 Mar;204(Pt B):112074. doi: 10.1016/j.envres.2021.112074. PMID: 34547251
Staphylococcus aureus surface protein G (sasG) allelic variants: correlation between biofilm formation and their prevalence in methicillin-resistant S. aureus (MRSA) clones. Carrera-Salinas A, González-Díaz A, Vázquez-Sánchez DA, Camoez M, Niubó J, Càmara J, Ardanuy C, Martí S, Domínguez MÁ; REIPI/GEIH Study Groups (E. Ruiz de Gopegui colaborador). Res Microbiol. 2022 Mar-Apr;173(3):103921. doi: 10.1016/j.resmic.2022.103921. PMID: 35091030
Pintado V, Ruiz-Garbajosa P, Aguilera-Alonso D, Baquero-Artigao F, Bou G, Cantón R, Grau S, Gutiérrez-Gutiérrez B, Larrosa N, Machuca I, Martínez Martínez L, Montero MM, Morte-Romea E, Oliver A, Paño-Pardo JR, Sorlí L. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gramnegative bacteria. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Dec 13:S2529-993X(22)00281-7. doi: 10.1016/j.eimce.2022.06.014. PMID: 36522272
Larrosa MN, Canut-Blasco A, Benito N, Cantón R, Cercenado E, Docobo-Pérez F, Fernández-Cuenca F, Fernández-Domínguez J, Guinea J, López-Navas A, Moreno MÁ, Morosini MI, Navarro F, Martínez-Martínez L, Oliver A. Spanish Antibiogram Committee (COESANT) recommendations for cumulative antibiogram reports. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Sep 26:S2529-993X(22)00177-0. doi: 10.1016/j.eimce.2022.09.002. Online ahead of print. PMID: 36175285
Reina J, Iglesias C. [EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus]. Rev Esp Quimioter. 2022 Nov 21:reina21nov2022. doi: 10.37201/req/096.2022. PMID: 36401806
Reina J, Costa C, Fernández-Billón M. Acute retinal necrosis caused by herpes simplex type 2. Med Clin (Barc). 2022 Nov 11;159(9):e63-e64. doi: 10.1016/j.medcli.2022.06.004. PMID: 36088127
Díaz Pérez D, Reina J, Arcay RM, Osona B. Changes in the incidence and clinical manifestations of paediatric respiratory infections of viral aetiology during the SARS-CoV-2 pandemic. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Oct;40(8):463-464. doi:10.1016/j.eimce.2022.05.003. PMID: 35624066
Reina J, Iglesias C. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]. Rev Esp Quimioter. 2022 Jun;35(3):236-240. doi:10.37201/req/002.2022. PMID: 35183067
Reina J. [The Victoria and Yamagata Lineages of Influenza B Viruses, unknown and undervalued]. Rev Esp Quimioter. 2022 Jun;35(3):231-235. doi: 10.37201/req/159.2021. PMID: 35180825
Reina J. Possible effect of the "original antigenic sin" in vaccination against new variants of SARS-CoV-2. Rev Clin Esp (Barc). 2022 Feb;222(2):91-92. doi:10.1016/j.rceng.2021.05.005. PMID: 34563486
Alonso Carballo A, Belzunce Capó JF, Iglesias Escobar C, García Gasalla M. Fever and migratory nodules in the lung. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Dec 30:S2529-993X(22)00292-1. doi: 10.1016/j.eimce.2022.12.002. PMID: 36588027
Gallardo Alfaro L; Lorente Montalvo P; Canellas M; Carandell E; Oliver A; Rojo E; Riera B; Llobera J; Bulilete O; Leiva A; Obieta A; Pascual V; Pericas P; Raduan C; Segura E; Vega V; Balearic COVID 19 P. Diagnostic accuracy of Panbio™ rapid antigen test for SARS-CoV-2 in paediatric population. BMC Pediatrics. 2023. 23 (1).
González J; de Batlle J; Benítez ID; Torres G; Santisteve S; Targa A; Gort Paniello C; Moncusí Moix A; Aguilà M; Seck F; Ceccato A; Ferrer R; Motos A; Riera J; Fernández L; Menéndez R; Lorente JA; Peñuelas O; Garcia Gasulla D; Peñasco Y; Ricart P; Palomares EA; Aguilera L; Rodríguez A; Varela MVB; Beteré B; Pozo Laderas JC; Solé Violan J; Salvador Adell I; Novo MA; Barberán J; Villar RA; Garnacho Montero J; Gómez JM; Ortiz AB; Lomas LT; Ubeda A; Catalán González M; Sánchez Miralles A; Varela IM; García RNJ; Franco N; Gumucio Sanguino VD; Bustamante Munguira E; Valdivia LJ; Caballero J; Gallego E; Rodríguez C; Castellanos Ortega A; Trenado J; Marin Corral J; Albaiceta GM; de la Torre MD; Loza Vázquez A; Vidal P; Añón JM; Pérez CC; Sagredo V; Carbonell N; Socias L; Barberà C; Estella A; Diaz E; de Gonzalo Calvo D;
Torres A; Barbé F; CIBERESUCICOVID P. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients. Archivos de Bronconeumología. 2023. 59 (4): 205-215.
Jordana Lluch E; Barceló IM; Escobar Salom M; Estévez MA; Zamorano L; Gómez Zorrilla S; Sendra E; Oliver A; Juan CR. The balance between antibiotic resistance and fitness/virulence in Pseudomonas aeruginosa: an update on basic knowledge and fundamental research. Frontiers in Microbiology. 2023. 141270999-1270999.
Pérez Vázquez M; López Causapé C; Corral Lugo A; McConnell MJ; Oteo Iglesias J; Oliver A; Martín Galiano AJ. Mutation Analysis in Regulator DNA-Binding Regions for Antimicrobial Efflux Pumps in 17,000 Pseudomonas aeruginosa Genomes. Microorganisms. 2023. 11 (10).
Agyeman AA; López Causapé C; Rogers KE; Lucas DD; Cortés Lara S; Gomis Font MA; Fraile Ribot P; Figuerola J; Lang Y; Franklyn E; Lee WL; Zhou J; Zhang Y; Bulitta JB; Boyce JD; Nation RL; Oliver A; Landersdorfer CB. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity. International Journal of Antimicrobial Agents. 2023. 62 (3): 106887-106887.
Tait JR; Harper M; Cortés Lara S; Rogers KE; López Causapé C; Smallman TR; Lang YZ; Lee WL; Zhou JQ; Bulitta JB; Nation RL; Boyce JD; Oliver A; Landersdorfer CB. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Antimicrobial Agents and Chemotherapy. 2023. 67 (8).
Atamna A; Margalit I; Ayada G; Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Fattah MA; Haquin J; Macgowan A; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodríguez Baño J; de Cueto M; Oliver A; De Gopegui ER; Cano A; Machuca I; Gozalo Marguello M; Martinez L; Gonzalez Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstei Y; Yahav D; ESCMID study group for infections in elderly. Outcomes of octogenarians and nonactogenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study. Infection. 2023. 51 (4): 1003-1012.
Galli F; Bindo F; Motos A; Fernández Barat L; Barbeta E; Gabarrús A; Ceccato A; Bermejo Martin JF; Ferrer R; Riera J; Peñuelas O; Lorente JA; de Gonzalo Calvo D; Menéndez R; Gonzalez J; Misuraca S; Palomeque A; Amaya Villar R; Añón JM; Mariño AB; Barberà C; Barberán J; Ortiz AB; Bustamante Munguira E; Caballero J; Cantón Bulnes ML; Pérez CC; Carbonell N; Catalán González M; de Frutos R; Franco N; Galbán C; Lago AL; Gumucio Sanguino VD; de la Torre MD; Díaz E; Estella A; Curto EG; García Garmendia JL; Gómez JM; Huerta A; García RNJ; Loza Vázquez A; Marin Corral J; Delgado MCM; de la Gándara AM; Varela IM; Messa JL; Albaiceta GM; Nieto MT; Novo MA; Peñasco Y; Pérez García F; Pozo Laderas JC; Ricart P; Sagredo V; Sánchez Miralles A; Chinesta SS; Roche Campo F; Socias L; Solé Violan J; Suarez Sipmann F; Lomas LT; Trenado J; Ubeda A; Valdivia LJ; Vidal P; Boado MV; Rodríguez A; Antonelli M; Blasi F; Barbé F; Torres A; CIBERESUCICOVID Project I. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients. Intensive Care Medicine. 2023. 49 (8): 934-945.
Diaz Caballero J; Wheatley RM; Kapel N; López Causape C; van der Schalk T; Quinn A; Shaw LP; Ogunlana L; Recanatini C; Xavier BB; Timbermont L; Kluytmans J; Ruzin A; Esser M; Malhotra Kumar S; Oliver A; MacLean RC. Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients. Nature Communications. 2023. 14 (1): 4083-4083.
López Argüello S; Montaner M; Sayed AR; Oliver A; Bulitta JB; Moya B. Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. Antimicrobial Agents and Chemotherapy. 2023. 67 (6): 160322-160322.
Escrihuela Vidal F; Kaasch AJ; Von Cube M; Rieg S; Kern WV; Seifert H; Song KH; Liao CH; Tilley R; Gott H; Scarborough M; Gordon C; Llewelyn MJ; Kuehl R; Morata L; Soriano A; Edgeworth J; De Gopegui ER; Nsutebu E; Cisneros JM; Fowler VG; Thwaites G; López Contreras J; Barlow G; Ternavasio De La Vega HG; Rodríguez Baño J; López Cortés LE; International Staphylococcus Aureus Collaboration Study Group TES. Impact of adherence to individual quality-of-care indicators on the prognosis of bloodstream infection due to Staphylococcus aureus: a prospective observational multicentre cohort. Clinical Microbiology and Infection. 2023. 29 (4): 498-505.
Cabot G; Kim K; Mark BL; Oliver A; Khajehpour M. Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/ Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2023. 67 (2):140922-140922.
Santos AL; Beckham JL; Liu DD; Li G; van Venrooy A; Oliver A; Tegos GP; Tour JM. Visible-Light-Activated Molecular Machines Kill Fungi by Necrosis Following Mitochondrial Dysfunction and Calcium Overload. Advanced Science. 2023. 10(10): 2205781-2205781.
Vinuela L; de Salazar A; Fuentes A; Serrano Conde E; Falces Romero I; Pinto A; Portilla I; Masia M; Peraire J; Gomez Sirvent JL; Sanchiz M; Iborra A; Baza B; Aguilera A; Olalla J; Espinosa N; Iribarren JA; Martinez Velasco M; Imaz A; Montero M; Rivero M; Suarez Garcia I; Macia MD; Galan JC; Perez Elias MJ; Garcia Fraile LJ; Moreno C; Garcia F. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021. Journal of Medical Virology. 2023. 95 (12).
Fernández Billón M; Llambías Cabot AE; Jordana Lluch E; Oliver A; Macià MD. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms. Biofilm. 2023. 5.
Gual Torrella A; López Causape C; Alejo Cancho I; Rojo Molinero E; Sanchez García G; Cortés Lara S; Rodríguez Moral MB; Berdonces Gonzalez P; Lopez de Goikoetxea MJ; Oliver A. Molecular characterization of a suspected IMP-type carbapenemase-producing Pseudomonas aeruginosa outbreak reveals two simultaneous outbreaks in a tertiary-care hospital. Infection Control and Hospital Epidemiology. 2023. 44 (11): 1801-1808.
Rivera A; Viñado B; Benito N; Docobo Pérez F; Fernández Cuenca F; Fernández Domínguez J; Guinea J; López Navas A; Moreno MA; Larrosa MN; Oliver A; Navarro F. Recommendations of the Spanish Antibiogram Committee (COESANT) for in vitro susceptibility testing of antimicrobial agents by disk. Enfermedades Infecciosas y Microbiologia Clinica. 2023. 41 (9): 571-576.
Sastre Femenia MA; Fernández Muñoz A; Gomis Font MA; Taltavull B; López Causapé C; Arca Suárez J; Martínez L; Cantón R; Larrosa N; Oteo Iglesias J; Zamorano L; Oliver A; GEMARA SEIMC C. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis. Lancet Regional Health-Europe. 2023. 34 
Adrover Jaume C; Clemente A; Rodríguez Urretavizcaya B; Vilaplana L; Marco MP; Rojo Molinero E; Oliver A; de la Rica R. A paper biosensor for overcoming matrix effects interfering with the detection of sputum pyocyanin with competitive immunoassays. Microchimica Acta. 2023. 190 (11).
Viver T; López Causapé C; Ribot Fraile P; Pérez Mazón C; López Solé D; Jiménez Guerra G; Taltavull B; López A. The molecular epidemiology of SARS-CoV-2 in the Pityusic Islands shows multiple introductions and fast replacements of variants in a touristic worldwide hot spot. Scientific Reports. 2023. 13 (1): 18053-18053
El Mammery A; de Arellano ER; Cañada García JE; Cercenado E; Villar Gómara L; Casquero García V; García Cobos S; Lepe JA; Bordes E; Calvo Montes J; Escartín NL; Cantón R; Pérez Vázquez M; Aracil B; Oteo Iglesias J; Spanish EARS Net GRP. An increase in erythromycin resistance in methicillin-susceptible Staphylococcus aureus from blood correlates with the use of macrolide/lincosamide/streptogramin antibiotics. EARS-Net Spain (2004-2020). Frontiers in Microbiology. 2023. 14.
Becerra Aparicio F; Gomez Zorrilla S; Hernandez Garcia M; Gijon D; Siverio A; Berbel D; Sanchez Carrillo C; Cercenado E; Rivera A; de Malet A; Xercavins M; de Gopegui ER; Canoura Fernandez L; Martinez JA; Seral C; Del Pozo JL; Cotarelo M; Diaz Reganon J; Canton R; Oliver A; Horcajada JP; Ruiz Garbajosa P. Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project). Journal of Antimicrobial Chemotherapy. 2023. 78 (9): 2291-2296.
Martínez Pomar N; Cunill V; Segura Guerrero M; Pol E; Oblitas DE; Pons J; Ayestarán I; Pruneda PC; Losada I; Toledo Pons N; Gasalla MG; Balaguer JMF. Hyperinflammatory Immune Response in COVID-19: Host Genetic Factors in Pyrin Inflammasome and Immunity to Virus in a Spanish Population from Majorca Island. Biomedicines. 2023. 11 (9).
Ortiz Cartagena C; Pablo Marcos D; Fernandez Garcia L; Blasco L; Pacios O; Bleriot I; Siller M; Lopez M; Fernandez J; Aracil B; Fraile Ribot PA; Garcia Fernandez S; Fernandez Cuenca F; Hernandez Garcia M; Canton R; Calvo Montes J; Tomas M. CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases. Microbiology Spectrum. 2023. 11 (4): 132923-132923.
Larrosa MN; Canut Blasco A; Benito N; Cantón R; Cercenado E; Docobo Pérez F; Fernández Cuenca F; Fernández Domínguez J; Guinea J; López Navas A; Moreno MA; Morosini MI; Navarro F; Martínez L; Oliver A. Spanish Antibiogram Committee (COESANT) recommendations for cumulative antibiogram reports. Enfermedades Infecciosas y Microbiología Clínica. 2023. 41 (7): 430-435.
Doménech Sánchez A; Laso E; Albertí S. Environmental surveillance of Pseudomonas aeruginosa in recreational waters in tourist facilities of the Balearic Islands, Spain (2016-2019). Travel Medicine and Infectious Disease. 2023. 54102622-102622
López Argüello S; Montaner M; Mármol Salvador A; Velázquez Escudero A; Docobo Pérez F; Oliver A; Moya B. Penicillin-Binding Protein Occupancy Dataset for 18 beta-Lactams and 4 beta-Lactamase Inhibitors in Neisseria gonorrhoeae. Microbiology Spectrum. 2023. 11 (3):69223-69223.
Villa L; Boga JA; Otero L; Vazquez F; Milagro A; Salmerón P; Vall Mayans M; Maciá MD; Bernal S; Piñeiro L. Phenotypic and Genotypic Antimicrobial Susceptibility Testing of Chlamydia trachomatis Isolates from Patients with Persistent or Clinical Treatment Failure in Spain. Antibiotics-Basel. 2023. 12 (6).
Pintado V; Ruiz Garbajosa P; Aguilera Alonso D; Baquero Artigao F; Boug G; Cantón R; Grauh S; Gutiérrez B; Larrosa N; Machuca I; Martínez LM; Montero MM; Morte Romea E; Oliver A; Paño Pardo JR; Sorlí L. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria. Enfermedades Infecciosas y Microbiología Clínica. 2023. 41 (6): 360-370.
García Fernández S; Calvo J; Cercenado E; Suárez Barrenechea AI; Fernandez Billón M; Castillo FJ; Gálvez Benítez L; Tubau F; Cerón R; Hernandez Cabezas A; Romo FG; Fariñas MC; Gómez M; Diaz Regañón J; Cantón R. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020. Revista Española de Quimioterapia. 2023. 36 (3):302-309.
Vázquez Morón S; Iglesias Caballero M; Lepe JA; Garcia F; Melón S; Marimon JM; de Viedma DG; Folgueira MD; Galán JC; López Causapé C; Benito Ruesca R; Alcoba Florez J; Candelas FG; de Toro M; Fajardo M; Ezpeleta C; Lázaro F; Castro SP; Cuesta I; Zaballos A; Pozo F; Casas I; RELECOV Network M. Enhancing SARSCoV-2 Surveillance through Regular Genomic Sequencing in Spain: The RELECOV Network. International Journal of Molecular Sciences. 2023. 24 (10).
Alonso García I; Vázquez Ucha JC; Lasarte Monterrubio C; González Mayo E; Lada Salvador P; Vela Fernández R; Aja Macaya P; Guijarro Sánchez P; Rumbo Feal S; Muíño Andrade M; Fernández González A; Martínez Guitián M; Beceiro A; Rodríguez Iglesias M; Oliver A; Arca Suárez J; Galán Sánchez F; Bou G. Simultaneous and divergent evolution of resistance to cephalosporin/beta-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections. Journal of Antimicrobial Chemotherapy. 2023. 78(5): 1195-1200.
Cercenado E; Rodríguez Baño J; Alfonso JL; Calbo E; Escosa L; Fernández Polo A; García Rodríguez J; Garnacho J; Gil Navarro MV; Grau S; Gudiol C; Horcajada JP; Larrosa N; Martínez C; Molina J; Nuvials X; Oliver A; Pano Pardo JR; Pérez Rodríguez MT; Ramírez P; Rey Biel P; Vidal P; Retamar Gentil P. Antimicrobial stewardship in hospitals: Expert recommendation guidance document for activities in specific populations, syndromes and other aspects (PROA-2) from SEIMC, SEFH, SEMPSPGS, SEMICYUC and SEIP. Enfermedades Infecciosas y Microbiología Clínica. 2023. 41 (4): 238-242.
López Causapé C; Maruri Aransolo A; Gomis Font MA; Penev I; Castillo MG; Mulet X; Caballero JD; del Campo R; Cantón R; Oliver A. Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clinical Microbiology And Infection. 2023. 29 (4): 5387-53813.
Piñeiro L; Villa L; Salmerón P; Maciá MD; Otero L; Vall Mayans M; Milagro A; Bernal S; Manzanal A; Ansa I; Cilla G. Genetic Characterization of Non-Lymphogranuloma venereum Chlamydia trachomatis Indicates Distinct Infection Transmission Networks in Spain. International Journal of Molecular Sciences. 2023. 24 (8).
Gavalda M; Vilchez H; Martin ML; Ruiz E; Ribas MA; Riera M. Endocarditis caused by Neisseria bacilliformis: a case report and review of literature. IDcases. 2023. 311725-1725.
González Alsina A; Mateu Borrás M; Doménech Sánchez A; Albertí S. Pseudomonas aeruginosa and the Complement System: A Review of the Evasion Strategies. Microorganisms. 2023. 11 (3).
Hernando Amado S; Lopez Causape C; Laborda P; Sanz Garcia F; Oliver A; Martinez JL. Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds. Microbiology Spectrum. 2023. 11(1).
Gracia Ahufinger I; López González L; Vasallo FJ; Galar A; Siller M; Pitart C; Bloise I; Torrecillas M; Gijón Cordero D; Viñado B; Castillo García J; Campo R; Mulet X; Madueño Alonso A; Chamizo López FJ; Arrastia Erviti M; Galán Sánchez F; Fernández Quejo M; Rodríguez Díaz JC; Gutiérrez Zufiaurre MN; Rodríguez Maresca MA; Ortega Lafont MD; Yagüe Guirao G; Chaves Blanco L; Colomina Rodríguez J; Vidal Acuña MR; Portillo ME; de Luna F; Centelles Serrano MJ; Azcona Gutiérrez JM; Campero A; Rey Cao S; Muñoz P; Calvo Montes J; Zboromyrska Y; Grandioso D; Càmara J; Cantón R; Larrosa Escartín N; Díaz Regañón J; Martinez Martínez L. The CARBA-MAP study: national mapping of carbapenemases in Spain (2014-2018). Frontiers in Microbiology. 2023. 141247804-1247804.
Pablo Marcos D; Siller M; Agueero J; Alvarez Justel A; Garcia Fernandez S; de la Fuente SV; Goicoechea P; Rodriguez Lozano J; Ocampo Sosa A; Lucas Fernandez J; Farinas MC; Fernandez J; Fraile Ribot PA; Aracil B; Oteo Iglesias J; Calvo Montes J. Are GES carbapenemases underdiagnosed? An allelic discrimination assay for their accurate detection and differentiation. Journal of Microbiological Methods. 2023. 207106694-106694.
Gomis Font MA; Sastre Femenia MA; Taltavull B; Cabot G; Oliver A. In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 2023. 78 (7): 1785-1794.
Escobar Salom M; Barceló IM; Jordana Lluch E; Torrens G; Oliver A; Juan CR. Bacterial virulence regulation through soluble peptidoglycan fragments sensing and response: knowledge gaps and therapeutic potential. Fems Microbiology Reviews. 2023. 47 (2).
Montaner M; Lopez Argüello S; Oliver A; Moya B. PBP Target Profiling by ß-Lactam and ß-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. Microbiology Spectrum. 2023. 11 (1).
Garcia Gasalla M; Berman Riu M; Rodriguez A; Iglesias A; Fraile Ribot PA; Toledo Pons N; Pol E; Ferré Beltrán A; Artigues Serra F; Martin Pena ML; Pons J; Murillas J; Oliver A; Riera M; Ferrer JM. Elevated complement C3 and increased CD8 and type 1 helper lymphocyte T populations in patients with post-COVID-19 condition. Cytokine. 2023. 169156295-156295.
Oliver A, Rojo-Molinero E, Arca-Suarez J, Beşli Y, Bogaerts P, Cantón R, Cimen C, Croughs PD, Denis O, Giske CG, Graells T, Daniel Huang TD, Iorga BI, Karatuna O, Kocsis B, Kronenberg A, López-Causapé C, Malhotra-Kumar S, Martínez LM, Mazzariol A, Meyer S, Naas T, Notermans DW, Oteo-Iglesias J, Pedersen T, Pirš M, Poeta P, Poirel L, Pournaras S, Sundsfjord A, Szabó D, Tambić-Andrašević A, Vatcheva-Dobrevska R, Vitkauskienė A, Jeannot K; ESGARS-ISARPAE members. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clin Microbiol Infect. 2023 Dec 29:S1198-743X(23)00634-1. doi: 10.1016/j.cmi.2023.12.026. PMID: 38160753
Høiby N, Moser C, Oliver A, Williams C, Ramage G, Borghi E, Azeredo J, Macia MD; ESGB board. To update or not to update the ESCMID guidelines for the diagnosis and treatment of biofilm infections - That is the question! The opinion of the ESGB board. Biofilm. 2023 Jul 3;6:100135. doi: 10.1016/j.bioflm.2023.100135. PMID: 38078061
Gomis-Font MA, Clari MA, López-Causapé C, Navarro D, Oliver A. Emergence of cefiderocol resistance during ceftazidime/avibactam treatment caused by a large genomic deletion, including ampD and piuCD genes, in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0119223. doi: 10.1128/aac.01192-23. PMID: 38063398
Hernández-García M, García-Castillo M, Nieto-Torres M, Bou G, Ocampo-Sosa A, Pitart C, Gracia-Ahufinger I, Mulet X, Pascual Á, Tormo N, Oliver A, Ruiz-Garbajosa P, Cantón R. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain. Eur J Clin Microbiol Infect Dis. 2023 Dec 2. doi: 10.1007/s10096-023-04697-4. PMID: 38041722
Pérez-Vázquez M, López-Causapé C, Corral-Lugo A, McConnell MJ, Oteo-Iglesias J, Oliver A, Martín-Galiano AJ. Mutation Analysis in Regulator DNA-Binding Regions for Antimicrobial Efflux Pumps in 17,000 Pseudomonas aeruginosa Genomes. Microorganisms. 2023 Oct 4;11(10):2486. doi: 10.3390/microorganisms11102486. PMID: 37894144
Adrover-Jaume C, Clemente A, Rodríguez-Urretavizcaya B, Vilaplana L, Marco MP, Rojo-Molinero E, Oliver A, de la Rica R. A paper biosensor for overcoming matrix effects interfering with the detection of sputum pyocyanin with competitive immunoassays. Mikrochim Acta. 2023 Oct 16;190(11):441. doi: 10.1007/s00604-023-06017-1. PMID: 37845505
Jordana-Lluch E, Barceló IM, Escobar-Salom M, Estévez MA, Zamorano L, Gómez-Zorrilla S, Sendra E, Oliver A, Juan C. The balance between antibiotic resistance and fitness/virulence in Pseudomonas aeruginosa: an update on basic knowledge and fundamental research. Front Microbiol. 2023 Sep 28;14:1270999. doi:10.3389/fmicb.2023.1270999. PMID: 37840717
Sastre-Femenia MÀ, Fernández-Muñoz A, Gomis-Font MA, Taltavull B, López-Causapé C, Arca-Suárez J, Martínez-Martínez L, Cantón R, Larrosa N, Oteo-Iglesias J, Zamorano L, Oliver A; GEMARA-SEIMC/CIBERINFEC Pseudomonas study Group. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis. Lancet Reg Health Eur. 2023 Sep 19;34:100736. doi: 10.1016/j.lanepe.2023.100736. eCollection 2023 Nov. PMID: 37753216
Gallardo-Alfaro L, Lorente-Montalvo P, Cañellas M, Carandell E, Oliver A, Rojo E, Riera B, Llobera J, Bulilete O; Balearic COVID-19 Pediatric Primary Care Research Group. Diagnostic accuracy of Panbio™ rapid antigen test for SARS-CoV-2 in paediatric population. BMC Pediatr. 2023 Aug 29;23(1):433. doi: 10.1186/s12887-023-04201-z. PMID: 37644389
Becerra-Aparicio F, Gómez-Zorrilla S, Hernández-García M, Gijón D, Siverio A, Berbel D, Sánchez-Carrillo C, Cercenado E, Rivera A, de Malet A, Xercavins M, Ruiz de Gopegui E, Canoura-Fernández L, Martínez JA, Seral C, Del Pozo JL, Cotarelo M, Díaz-Regañón J, Cantón R, Oliver A, Horcajada JP, Ruiz-Garbajosa P. Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project). J Antimicrob Chemother. 2023 Sep 5;78(9):2291-2296. doi: 10.1093/jac/dkad234. PMID: 37533351
Garcia-Gasalla M, Berman-Riu M, Rodriguez A, Iglesias A, Fraile-Ribot PA, Toledo-Pons N, Pol-Pol E, Ferré-Beltrán A, Artigues-Serra F, Martin-Pena ML, Pons J, Murillas J, Oliver A, Riera M, Ferrer JM. Elevated complement C3 and increased CD8 and type 1 helper lymphocyte T populations in patients with post-COVID-19 condition. Cytokine. 2023 Sep;169:156295. doi: 10.1016/j.cyto.2023.156295. PMID: 37453328
Diaz Caballero J, Wheatley RM, Kapel N, López-Causapé C, Van der Schalk T, Quinn A, Shaw LP, Ogunlana L, Recanatini C, Xavier BB, Timbermont L, Kluytmans J, Ruzin A, Esser M, Malhotra-Kumar S, Oliver A, MacLean RC. Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients.Nat Commun. 2023 Jul 12;14(1):4083. doi: 10.1038/s41467-023-39416-2. PMID: 37438338
Tait JR, Harper M, Cortés-Lara S, Rogers KE, López-Causapé C, Smallman TR, Lang Y, Lee WL, Zhou J, Bulitta JB, Nation RL, Boyce JD, Oliver A, Landersdorfer CB. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. PMID: 37428034
Agyeman AA*, López-Causapé C*, Rogers KE, Lucas DD, Cortés-Lara S, Gomis-Font MA, Fraile-Ribot P, Figuerola J, Lang Y, Franklyn ERT, Lee WL, Zhou J, Zhang Y, Bulitta JB, Boyce JD, Nation RL, Oliver A*, Landersdorfer CB*. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity. Int J Antimicrob Agents. 2023 Sep;62(3):106887. doi: 10.1016/j.ijantimicag.2023.106887. PMID: 37315906
Gomis-Font MA, Sastre-Femenia MÀ, Taltavull B, Cabot G, Oliver A. In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2023 Jul 5;78(7):1785-1794. doi:10.1093/jac/dkad172. PMID: 37253034
Fernández-Billón M, Llambías-Cabot AE, Jordana-Lluch E, Oliver A, Macià MD. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms. Biofilm. 2023 May 2;5:100129. doi: 10.1016/j.bioflm.2023.100129. Dec. PMID: 37205903
López-Argüello S, Montaner M, Sayed AR, Oliver A, Bulitta JB, Moya B. Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. doi: 10.1128/aac.01603-22. PMID: 37199612
Gual-de-Torrella A, López-Causape C, Alejo-Cancho I, Rojo-Molinero E, Sanchez-García G, Cortés-Lara S, Rodríguez Moral MB, Berdonces-Gonzalez P, Lopez de Goikoetxea MJ, Oliver A. Molecular characterization of a suspected IMP-type carbapenemase-producing Pseudomonas aeruginosa outbreak reveals two simultaneous outbreaks in a tertiary-care hospital. Infect Control Hosp Epidemiol. 2023 Nov;44(11):1801-1808. doi:10.1017/ice.2023.75. PMID: 37138359
López-Argüello S, Montaner M, Mármol-Salvador A, Velázquez-Escudero A, Docobo-Pérez F, Oliver A, Moya B. Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. Microbiol Spectr. 2023 Jun 15;11(3):e0069223. doi: 10.1128/spectrum.00692-23. PMID: 37093051
Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, Aja-Macaya P, Guijarro-Sánchez P, Rumbo-Feal S, Muíño-Andrade M, Fernández-González A, Martínez-Guitián M, Beceiro A, Rodríguez-Iglesias M, Oliver A, Arca-Suárez J, Galán-Sánchez F, Bou G. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections. J Antimicrob Chemother. 2023 May 3;78(5):1195-1200. doi: 10.1093/jac/dkad062. PMID: 36918743
Escobar-Salom M, Barceló IM, Jordana-Lluch E, Torrens G, Oliver A, Juan C. Bacterial virulence regulation through soluble peptidoglycan fragments sensing and response: knowledge gaps and therapeutic potential. FEMS Microbiol Rev. 2023 Mar 10;47(2):fuad010. doi:10.1093/femsre/fuad010.PMID: 36893807
Santos AL, Beckham JL, Liu D, Li G, van Venrooy A, Oliver A, Tegos GP, Tour JM. Visible-Light-Activated Molecular Machines Kill Fungi by Necrosis Following Mitochondrial Dysfunction and Calcium Overload. Adv Sci (Weinh). 2023 Apr;10(10):e2205781. doi:10.1002/advs.202205781. PMID: 36715588.
Cabot G, Kim K, Mark BL, Oliver A, Khajehpour M. Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0140922. doi: 10.1128/aac.01409-22. PMID: 36715512
Atamna A, Margalit I, Ayada G, Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Fattah MA, Haquin J, Macgowan A, Chazan B, Yanovskay A, Ami RB, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Rodríguez-Baño J, de Cueto M, Oliver A, de Gopegui ER, Cano A, Machuca I, Gozalo-Marguello M, Martinez-Martinez L, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstei Y, Yahav D; ESCMID study group for infections in elderly (ESGIE).Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study. Infection. 2023 Aug;51(4):1003-1012. doi: 10.1007/s15010-022-01973-x. PMID: 36571672
Hernando-Amado S, López-Causapé C, Laborda P, Sanz-García F, Oliver A, Martínez JL. Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds. Microbiol Spectr. 2023 Feb 14;11(1):e0227622. doi: 10.1128/spectrum.02276-22. PMID: 36533961
Pintado V, Ruiz-Garbajosa P, Aguilera-Alonso D, Baquero-Artigao F, Bou G, Cantón R, Grau S, Gutiérrez-Gutiérrez B, Larrosa N, Machuca I, Martínez Martínez L, Montero MM, Morte-Romea E, Oliver A, Paño-Pardo JR, Sorlí L. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gramnegative bacteria. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jun-Jul;41(6):360-370. doi:10.1016/j.eimce.2022.06.014. PMID: 36522272
Montaner M, Lopez-Argüello S, Oliver A, Moya B. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. Microbiol Spectr. 2023 Feb 14;11(1):e0303822. doi: 10.1128/spectrum.03038-22. PMID: 36475840
López-Causapé C, Maruri-Aransolo A, Gomis-Font MA, Penev I, Castillo MG, Mulet X, de Dios Caballero J, Campo RD, Cantón R, Oliver A. Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect. 2023 Apr;29(4):538.e7-538.e13. doi: 10.1016/j.cmi.2022.11.014. PMID: 36435424
Gracia-Ahufinger I, López-González L, Vasallo FJ, Galar A, Siller M, Pitart C, Bloise I, Torrecillas M, Gijón-Cordero D, Viñado B, Castillo-García J, Campo R, Mulet X, Madueño-Alonso A, Chamizo-López FJ, Arrastia-Erviti M, Galán-Sánchez F, Fernández-Quejo M, Rodríguez-Díaz JC, Gutiérrez-Zufiaurre MN, Rodríguez-Maresca MA, Ortega-Lafont MDP, Yagüe-Guirao G, Chaves-Blanco L, Colomina-Rodríguez J, Vidal-Acuña MR, Portillo ME, Franco-Álvarez de Luna F, Centelles-Serrano MJ, Azcona-Gutiérrez JM, Delgado-Iribarren García Campero A, Rey-Cao S, Muñoz P, Calvo-Montes J, Zboromyrska Y, Grandioso D, Càmara J, Cantón R, Larrosa-Escartín N, Díaz-Regañón J, Martínez-Martínez L.The CARBA-MAP study: national mapping of carbapenemases in Spain (2014-2018). Front Microbiol. 2023 Sep 8;14:1247804. doi: 10.3389/fmicb.2023.1247804. PMID: 37744921
Sojo-Dorado J, López-Hernández I, Hernández-Torres A, Retamar-Gentil P, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Álvarez RM, Dueñas CJ, Calvo-Montes J, Lecuona M, Pomar V, Borreguero I, Palomo-Jiménez V, Docobo-Pérez F, Pascual Á, Rodríguez-Baño J. Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial. J Antimicrob Chemother. 2023 Jul 5;78(7):1658-1666. doi: 10.1093/jac/dkad147. PMID: 37260299
Ortiz-Cartagena C, Pablo-Marcos D, Fernández-García L, Blasco L, Pacios O, Bleriot I, Siller M, López M, Fernández J, Aracil B, Fraile-Ribot PA, García-Fernández S, Fernández-Cuenca F, Hernández-García M, Cantón R, Calvo-Montes J, Tomás M. CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases. Microbiol Spectr. 2023 Aug 17;11(4):e0132923. doi: 10.1128/spectrum.01329-23. PMID: 37466441
Pablo-Marcos D, Siller M, Agüero J, Álvarez-Justel A, García-Fernández S, de la Fuente SV, Goicoechea P, Rodríguez-Lozano J, Ocampo-Sosa A, Lucas-Fernández J, Fariñas MC, Fernández J, Fraile-Ribot PA, Aracil B, Oteo-Iglesias J, Calvo-Montes J. Are GES carbapenemases underdiagnosed? An allelic discrimination assay for their accurate detection and differentiation. J Microbiol Methods. 2023 Apr;207:106694. doi:10.1016/j.mimet.2023.106694. PMID: 36871870
Viver T, López-Causapé C, Ribot-Fraile P, Pérez-Mazón C, López-Solé D, Jiménez-Guerra G, Taltavull B, López-López A. The molecular epidemiology of SARS-CoV-2 in the Pityusic Islands shows multiple introductions and fast replacements of variants in a touristic worldwide hot spot. Sci Rep. 2023 Oct 23;13(1):18053. doi: 10.1038/s41598-023-44668-5. PMID: 37872265
Vázquez-Morón S, Iglesias-Caballero M, Lepe JA, Garcia F, Melón S, Marimon JM, García de Viedma D, Folgueira MD, Galán JC, López-Causapé C, Benito-Ruesca R, Alcoba-Florez J, Gonzalez Candelas F, Toro M, Fajardo M, Ezpeleta C, Lázaro F, Pérez Castro S, Cuesta I, Zaballos A, Pozo F, Casas I, On Behalf Of Relecov Network Members.Enhancing SARSCoV-2 Surveillance through Regular Genomic Sequencing in Spain: The RELECOV Network. Int J Mol Sci. 2023 May 10;24(10):8573. doi: 10.3390/ijms24108573. PMID: 37239920
Viñuela L, de Salazar A, Fuentes A, Serrano-Conde E, Falces-Romero I, Pinto A, Portilla I, Masiá M, Peraire J, Gómez-Sirvent JL, Sanchiz M, Iborra A, Baza B, Aguilera A, Olalla J, Espinosa N, Iribarren JA, Martínez-Velasco M, Imaz A, Montero M, Rivero M, Suarez-García I, Maciá MD, Galán JC, Perez-Elias MJ, García-Fraile LJ, Moreno C, Garcia F. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021. J Med Virol. 2023 Dec;95(12) e29287. doi:10.1002/jmv.29287. PMID: 38084763.
Piñeiro L, Villa L, Salmerón P, Maciá MD, Otero L, Vall-Mayans M, Milagro A, Bernal S, Manzanal A, Ansa I, Cilla G. Genetic Characterization of Non-Lymphogranuloma venereum Chlamydia trachomatis Indicates Distinct Infection Transmission Networks in Spain. Int J Mol Sci. 2023 Apr 8;24(8):6941. doi: 10.3390/ijms24086941.PMID: 37108105
Macià M, Borghi Elisa, Oliver A. (2023). Eurobiofilms 2022: A translational perspective of biofilm-related PERSISTENT infections. Biofilm. 100168. 10.1016/j.bioflm.2023.100168.
Suárez-Bode, L.; López-Causapé, C.; Arcay, R.M.; Oliver, A.; Mena, A. Whole Genome Sequencing Evidences High Rates of Relapse in Clostridioides difficile Infection Caused by the Epidemic Ribotype 106. Appl. Microbiol. 2023, 3, 64-75. https://doi.org/10.3390/applmicrobiol3010005
El Mammery A, Ramírez de Arellano E, Cañada-García JE, Cercenado E, Villar-Gómara L, Casquero-García V, García-Cobos S, Lepe JA, Ruiz de Gopegui E, Calvo-Montes J, Larrosa Escartín N, Cantón R, Pérez-Vázquez M, Aracil B, Oteo-Iglesias J. An increase in erythromycin resistance in methicillin-susceptible Staphylococcus aureus from blood correlates with the use of macrolide/lincosamide/streptogramin antibiotics. EARS-Net Spain (2004-2020). Front Microbiol. 2023 Sep 26;14:1220286. doi: 10.3389/fmicb.2023.1220286. PMID: 37822743.
Gijón D, García-Castillo J, Fernández-López MC, Bou G, Siller M, Calvo-Montes J, Pitart C, Vila J, Torno N, Gimeno C, Cruz H, Ramos H, Mulet X, Oliver A, Ruiz-Garbajosa P, Canton R. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal. Rev Esp Quimioter. 2023 Oct 26:gijon26oct2023. doi: 10.37201/req/098.2023. PMID: 37882320
Cercenado E, Rodríguez-Baño J, Alfonso JL, Calbo E, Escosa L, Fernández-Polo A, García-Rodríguez J, Garnacho J, Gil-Navarro MV, Grau S, Gudiol C, Horcajada JP, Larrosa N, Martínez C, Molina J, Nuvials X, Oliver A, Paño-Pardo JR, Pérez-Rodríguez MT, Ramírez P, Rey-Biel P, Vidal P, Retamar-Gentil P. Antimicrobial stewardship in hospitals: Expert recommendation guidance document for activities in specific populations, syndromes and other aspects (PROA-2) from SEIMC, SEFH, SEMPSPGS, SEMICYUC and SEIP. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Apr;41(4):238-242. doi: 10.1016/j.eimce.2022.05.013. PMID: 36610836
Rivera A, Viñado B, Benito N, Docobo-Pérez F, Fernández-Cuenca F, Fernández-Domínguez J, Guinea J, López-Navas A, Moreno MÁ, Larrosa MN, Oliver A, Navarro F. Recommendations of the Spanish Antibiogram Committee (COESANT) for in vitro susceptibility testing of antimicrobial agents by disk diffusion. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Nov;41(9):571-576. doi: 10.1016/j.eimce.2022.12.009. PMID: 36610835
Larrosa MN, Canut-Blasco A, Benito N, Cantón R, Cercenado E, Docobo-Pérez F, Fernández-Cuenca F, Fernández-Domínguez J, Guinea J, López-Navas A, Moreno MÁ, Morosini MI, Navarro F, Martínez-Martínez L, Oliver A. Spanish Antibiogram Committee (COESANT) recommendations for cumulative antibiogram reports. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Aug-Sep;41(7):430-435. doi: 10.1016/j.eimce.2022.09.002. PMID: 36175285
García-Fernández S, Calvo J, Cercenado E, Suárez-Barrenechea AI, Fernández-Billón M, Castillo FJ, Gálvez-Benítez L, Tubau F, Figueroa Cerón RE, Hernández-Cabezas A, González Romo F, Fariñas MC, Gómez M, Díaz-Regañón J, Cantón R. Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020. Rev Esp Quimioter. 2023 Jun;36(3):302-309. PMID: 36951688
Reina J, Iglesias C. [Detection of co-infection by Herpes simplex virus type 1 and type 2 in female genital ulcers]. Rev Esp Quimioter. 2023 Oct;36(5):547-548. doi:10.37201/req/041.2023. PMID: 37465868
Reina J, González de Herrero E. [Alternative viral diagnosis in suspected monkeypox]. Rev Esp Quimioter. 2023 Aug;36(4):442-443. doi: 10.37201/req/003.2023. PMID: 37134179
Reina J, Iglesias C. Vaccines against monkeypox. Med Clin (Engl Ed). 2023 Apr 6;160(7):305-309. doi: 10.1016/j.medcle.2023.01.005. PMID: 37033199
Reina J. The new generation of messenger RNA (mRNA) vaccines against influenza. Enferm Infecc Microbiol Clin (Engl Ed). 2023 May;41(5):301-304. doi:10.1016/j.eimce.2022.07.006. PMID: 35906174
Adrover-Jaume C, Clemente A, Viana-Ramírez J, Rojo-Molinero E, Oliver A, de la Rica R. A multirange paper-based analytical device for identifying low, moderate, and high P. aeruginosa bacterial loads in sputum samples. Biosens Bioelectron. 2024 Dec 24;272:117097. doi: 10.1016/j.bios.2024.117097. Online ahead of print. PMID: 39742786. 
López-Argüello S, Alcoceba E, Ordóñez P, Taltavull B, Cabot G, Gomis-Font MA, Oliver A, Moya B. Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. PLoS Pathog. 2024 Dec 31;20(12):e1012783. doi: 10.1371/journal.ppat.1012783. Online ahead of print. PMID: 39739989 
Roson-Calero N, Gomis Font MA, Ruiz-Soriano A, Just-Baringo X, Pachón-Ibáñez ME, Salvador JP, Marco MP, Giralt E, Oliver A, Ballesté-Delpierre C, Vila J. In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide. Antimicrob Agents Chemother. 2024 Dec 23:e0145924. doi: 10.1128/aac.01459-24. Online ahead of print. PMID: 39714156 
Valik JK, Giske CG, Hasan B, Gozalo-Margüello M, Martínez-Martínez L, Premru MM, Martinčič Ž, Beović B, Maraki S, Zacharioudaki M, Kofteridis D, McCarthy K, Paterson D, Cueto M, Morales I, Leibovici L, Babich T, Granath F, Rodríguez-Baño J, Oliver A, Yahav D, Nauclér P. Genomic virulence markers are associated with severe outcomes in patients with Pseudomonas aeruginosa bloodstream infection. Commun Med (Lond). 2024 Dec 11;4(1):264. doi: 10.1038/s43856-024-00696-4. PMID: 39663376 
Fernández-Billón M, Jordana-Lluch E, Llambías-Cabot AE, Gomis-Font MA, Fraile-Ribot P, Torrandell RI, Colman-Vega PJ, Murillo Ó, Macià MD, Oliver A. Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms. Biofilm. 2024 Oct 22;8:100231. doi: 10.1016/j.bioflm.2024.100231. eCollection 2024 Dec. PMID: 39555141 
Recanatini C, van Werkhoven CH, van der Schalk TE, Paling F, Hazard D, Timbermont L, Torrens G, DiGiandomenico A, Esser MT, Wolkewitz M, Sifakis F, Goossens H, Bonten M, Oliver A, Malhotra-Kumar S, Kluytmans J; ASPIRE-ICU Study Team. Impact of Pseudomonas aeruginosa carriage on intensive care unit-acquired pneumonia: a European multicentre prospective cohort study. Clin Microbiol Infect. 2024 Nov 10:S1198-743X(24)00533-0. doi: 10.1016/j.cmi.2024.11.007. Online ahead of print. PMID: 39532190 
Hidalgo-Tenorio C, Bou G, Oliver A, Rodríguez-Aguirregabiria M, Salavert M, Martínez-Martínez L. The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review. Drugs. 2024 Dec;84(12):1519-1539. doi: 10.1007/s40265-024-02102-8. Epub 2024 Oct 28. PMID: 39467989 
Herrera C, Gomis-Font MA, López-Causapé C, Díez-Aguilar M, Fraile-Ribot PA, Cardeñoso LM, Oliver A. Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0116424. doi: 10.1128/aac.01164-24. Epub 2024 Oct 21. PMID: 39431817 
Maruri-Aransolo A, Hernandez-García M, Barbero R, Michelena M, Pastor-Vivero MD, Mondejar-Lopez P, Solé A, Cantón R, Caballero-Pérez JD; GEIFQ study group (López-Causapé C, Oliver A colaboradores). Genomic characterization of MRSA recovered from people with cystic fibrosis during two Spanish multicentre studies (2013 and 2021). JAC Antimicrob Resist. 2024 Oct 17;6(5):dlae160. doi: 10.1093/jacamr/dlae160. eCollection 2024 Oct. PMID: 39429234 
Cortes-Lara S, Medina-Reatiga P, Barrio-Tofiño ED, Gomis-Font MA, Cabot G, Gómez-Romano F, Ayestarán I, Colomar A, Palou-Rotger A, Oteo-Iglesias J, Campo RD, Cantón R, Horcajada JP, López-Causapé C, Oliver A. Monitoring of Pseudomonas aeruginosa mutational resistome dynamics using an enrichment panel for direct sequencing of clinical samples. EBioMedicine. 2024 Oct;108:105367. doi: 10.1016/j.ebiom.2024.105367. Epub 2024 Sep 26. PMID: 39332391 
Lindon S, Shah S, Gifford DR, Lood C, Gomis Font MA, Kaur D, Oliver A, MacLean RC, Wheatley RM Antibiotic resistance alters the ability of Pseudomonas aeruginosa to invade bacteria from the respiratory microbiome. Evol Lett. 2024 Jun 30;8(5):735-747. doi: 10.1093/evlett/qrae030. eCollection 2024 Sep. PMID: 39328287 
González-Pinto L, Blanco-Martín T, Alonso-García I, Rodríguez-Pallares S, Outeda-García M, Gomis-Font MA, Fraile-Ribot PA, Vázquez-Ucha JC, González-Bello C, Beceiro A, Oliver A, Bou G, Arca-Suárez J. Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa. J Antimicrob Chemother. 2024 Nov 4;79(11):3023-3028. doi: 10.1093/jac/dkae326. PMID: 39287983 
Li H, Oliver A, Shields RK, Kamat S, Stone G, Estabrook M. Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0067024. doi: 10.1128/aac.00670-24. Epub 2024 Sep 10. PMID: 39254297 
Mancheño-Losa M, Murillo O, Benavent E, Sorlí L, Riera M, Cobo J, Benito N, Morata L, Ribera A, Sobrino B, Fernández-Sampedro M, Múñez E, Bahamonde A, Barbero JM, Del Toro MD, Villa J, Rigo-Bonnin R, Luque S, García-Luque I, Oliver A, Esteban J, Lora-Tamayo J. Efficacy and safety of colistin plus beta-lactams for bone and joint infection caused by fluoroquinolone-resistant gram-negative bacilli: a prospective multicenter study. Infection. 2024 Sep 9. doi: 10.1007/s15010-024-02379-7. Online ahead of print. PMID: 39249177 
Montero MM, Domene-Ochoa S, Prim N, Ferola E, López-Causapé C, Echeverria D, Morisaki MFA, Vega-Toribio V, Sorlí L, Luque S, Padilla E, Oliver A, Horcajada JP. Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing Pseudomonas aeruginosa: insights from the hollow-fiber infection model. Infect Dis (Lond). 2025 Jan;57(1):81-88. doi: 10.1080/23744235.2024.2396882. Epub 2024 Aug 30. PMID: 39212630 
Arcay R, Barceló-Nicolau M, Suárez L, Martín L, Reigada R, Höring M, Liebisch G, Garrido C, Cabot G, Vílchez H, Cortés-Lara S, González de Herrero E, López-Causapé C, Oliver A, Barceló-Coblijn G, Mena A. Gut microbiome and plasma lipidome analysis reveals a specific impact of Clostridioides difficile infection on intestinal bacterial communities and sterol metabolism. mBio. 2024 Oct 16;15(10):e0134724. doi: 10.1128/mbio.01347-24. Epub 2024 Aug 27. PMID: 39189787 
Fuhs DT, Cortés-Lara S, Tait JR, Rogers KE, López-Causapé C, Lee WL, Shackleford DM, Nation RL, Oliver A, Landersdorfer CB. The effects of single and multiple resistance mechanisms on bacterial response to meropenem. Clin Microbiol Infect. 2024 Oct;30(10):1276-1283. doi: 10.1016/j.cmi.2024.06.026. Epub 2024 Aug 5. PMID: 39107161 
González-Pinto L, Alonso-García I, Blanco-Martín T, Camacho-Zamora P, Fraile-Ribot PA, Outeda-García M, Lasarte-Monterrubio C, Guijarro-Sánchez P, Maceiras R, Moya B, Juan C, Vázquez-Ucha JC, Beceiro A, Oliver A, Bou G, Arca-Suárez J. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa. J Antimicrob Chemother. 2024 Oct 1;79(10):2591-2597. doi: 10.1093/jac/dkae263. PMID: 39073766 
Sendra E, Fernández-Muñoz A, Zamorano L, Oliver A, Horcajada JP, Juan C, Gómez-Zorrilla S. Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective. Infection. 2024 Aug;52(4):1235-1268. doi: 10.1007/s15010-024-02313-x. Epub 2024 Jul 2. PMID: 38954392 
Gómez-Zorrilla S, Becerra-Aparicio F, Sendra E, Zamorano L, Grau I, Pintado V, Padilla B, Benito N, Boix-Palop L, Fariñas MC, Peñaranda M, Gamallo MR, Martinez JA, Morte-Romea E, Del Pozo JL, López Montesinos I, Durán-Jordà X, Ponz R, Cotarelo M, Cantón R, Oliver A, Ruiz-Garbajosa P, Horcajada JP; ITUBRAS-2 Group. Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections: a post-hoc analysis of a multicentre prospective cohort in Spain. J Hosp Infect. 2024 Sep;151:173-185. doi: 10.1016/j.jhin.2024.05.020. Epub 2024 Jun 28. PMID: 3894539 
Santerre Henriksen A, Arena F, Attwood M, Canton R, Gatermann S, Naas T, Morrissey I, Longshaw C; ARTEMIS Study Investigators (Oliver A, colaborador). In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations. Microbiol Spectr. 2024 Jun 21;12(8):e0418123. doi: 10.1128/spectrum.04181-23. Online ahead of print. PMID: 38904361 
Maruri-Aransolo A, López-Causapé C, Hernández-García M, García-Castillo M, Caballero-Pérez JD, Oliver A, Cantón R. In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain. J Antimicrob Chemother. 2024 Jun 3;79(6):1432-1440. doi: 10.1093/jac/dkae126. PMID: 38708553 
Vaquer A, Adrover-Jaume C, Clemente A, Viana J, Rodríguez R, Rojo-Molinero E, Oliver A, de la Rica R. OriPlex: Origami-enabled multiplexed detection of respiratory pathogens. Biosens Bioelectron. 2024 Aug 1;257:116341. doi: 10.1016/j.bios.2024.116341. Epub 2024 Apr 25. PMID: 38677019 
Breen SKJ, Harper M, López-Causapé C, Rogers KE, Tait JR, Smallman TR, Lang Y, Lee WL, Zhou J, Zhang Y, Bulitta JB, Nation RL, Oliver A, Boyce JD, Landersdorfer CB. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing. Int J Antimicrob Agents. 2024 Jun;63(6):107161. doi: 10.1016/j.ijantimicag.2024.107161. Epub 2024 Mar 30. PMID: 38561094 
Barceló IM, Escobar-Salom M, Cabot G, Perelló-Bauzà P, Jordana-Lluch E, Taltavull B, Torrens G, Rojo-Molinero E, Zamorano L, Pérez A, Oliver A, Juan C. Transferable AmpCs in Klebsiella pneumoniae: interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications. Antimicrob Agents Chemother. 2024 May 2;68(5):e0131523. doi: 10.1128/aac.01315-23. Epub 2024 Mar 22. PMID: 38517189 
Blanco-Martín T, Alonso-García I, González-Pinto L, Outeda-García M, Guijarro-Sánchez P, López-Hernández I, Pérez-Vázquez M, Aracil B, López-Cerero L, Fraile-Ribot P, Oliver A, Vázquez-Ucha JC, Beceiro A, Bou G, Arca-Suárez J; GEMARA/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT). Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions. Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19. PMID: 38513748 
Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, Morrissey I, Longshaw C; ARTEMIS Study Investigators. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiol Spectr. 2024 Apr 2;12(4):e0383623. doi: 10.1128/spectrum.03836-23. Epub 2024 Mar 14. PMID: 38483164 
Escobar-Salom M, Barceló IM, Rojo-Molinero E, Jordana-Lluch E, Cabot G, Oliver A, Juan C. In vitro activity of human defensins HNP-1 and hBD-3 against multidrug-resistant ESKAPE Gram-negatives of clinical origin and selected peptidoglycan recycling-defective mutants. Microbiol Spectr. 2024 Apr 2;12(4):e0035824. doi: 10.1128/spectrum.00358-24. PMID: 38441982 
Santos AL, Liu D, van Venrooy A, Beckham JL, Oliver A, Tegos GP, Tour JM. Nonlethal Molecular Nanomachines Potentiate Antibiotic Activity Against Gram-Negative Bacteria by Increasing Cell Permeability and Attenuating Efflux. ACS Nano. 2024 Jan 30;18(4):3023-3042. doi: 10.1021/acsnano.3c08041. Epub 2024 Jan 19. PMID: 38241477 
Barceló IM, Escobar-Salom M, Jordana-Lluch E, Torrens G, Oliver A, Juan C.Filling knowledge gaps related to AmpC-dependent β-lactam resistance in Enterobacter cloacae. Sci Rep. 2024 Jan 2;14(1):189. doi: 10.1038/s41598-023-50685-1. PMID: 38167986 
Oliver A, Rojo-Molinero E, Arca-Suarez J, Beşli Y, Bogaerts P, Cantón R, Cimen C, Croughs PD, Denis O, Giske CG, Graells T, Daniel Huang TD, Iorga BI, Karatuna O, Kocsis B, Kronenberg A, López-Causapé C, Malhotra-Kumar S, Martínez LM, Mazzariol A, Meyer S, Naas T, Notermans DW, Oteo-Iglesias J, Pedersen T, Pirš M, Poeta P, Poirel L, Pournaras S, Sundsfjord A, Szabó D, Tambić-Andrašević A, Vatcheva-Dobrevska R, Vitkauskienė A, Jeannot K; ESGARS-ISARPAE members. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group. Clin Microbiol Infect. 2024 Apr;30(4):469-480. doi: 10.1016/j.cmi.2023.12.026. PMID: 38160753 Emergence of cefiderocol resistance during ceftazidime/avibactam treatment caused by a large genomic deletion, including ampD and piuCD genes, in Pseudomonas aeruginosa. 
Gomis-Font MA, Clari MA, López-Causapé C, Navarro D, Oliver A. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0119223. doi: 10.1128/aac.01192-23. PMID: 38063398 
Hernández-García M, García-Castillo M, Nieto-Torres M, Bou G, Ocampo-Sosa A, Pitart C, Gracia-Ahufinger I, Mulet X, Pascual Á, Tormo N, Oliver A, Ruiz-Garbajosa P, Cantón R. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain. Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):279-296. doi: 10.1007/s10096-023-04697-4. Epub 2023 Dec 2. PMID: 38041722 
Guinea J, Alcoceba E, Padilla E, Ramírez A, De Carolis E, Sanguinetti M, Muñoz-Algarra M, Durán-Valle T, Quiles-Melero I, Merino P, González-Romo F, Sánchez-García A, Gómez-García-de-la-Pedrosa E, Pérez-Ayala A, Mantecón-Vallejo MÁ, Pemán J, Cuétara MS, Zurita ND, García-Esteban C, Martínez-Jiménez MDC, Sánchez Castellano MÁ, Reigadas E, Muñoz P, Escribano P. Fluconazole-resistant Candida parapsilosis: fast detection of the Y132F ERG11p substitution, and a proposed microsatellite genotyping scheme. Clin Microbiol Infect. 2024 Nov;30(11):1447-1452. doi: 10.1016/j.cmi.2024.07.002. Epub 2024 Jul 14. PMID: 39002661 
Mesquida A, Alcoceba E, Padilla E, Ramírez A, Merino P, González-Romo F, De Carolis E, Sanguinetti M, Mantecón-Vallejo MLÁ, Muñoz-Algarra M, Durán-Valle T, Pérez-Ayala A, Gómez-García-de-la-Pedrosa E, Del Carmen Martínez-Jiménez M, Sánchez-Castellano MÁ, Quiles-Melero I, Cuétara MS, Sánchez-García A, Muñoz P, Escribano P, Guinea J; CANDIMAD study group. Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole-resistance profiles associated with the Y132F ERG11p substitution. Mycoses. 2024 Mar;67(3):e13706. doi: 10.1111/myc.13706. PMID: 38438313 
Ramírez de Arellano E, Saavedra-Lozano J, Villalón P, Jové-Blanco A, Grandioso D, Sotelo J, Gamell A, González-López JJ, Cervantes E, Gónzalez MJ, Rello-Saltor V, Esteva C, Sanz-Santaeufemia F, Yagüe G, Manzanares Á, Brañas P, Ruiz de Gopegui E, Carrasco-Colom J, García F, Cercenado E, Mellado I, Del Castillo E, Pérez-Vazquez M, Oteo-Iglesias J, Calvo C; Spanish PedGAS-Net/CIBERINFEC GAS Study Group. Clinical, microbiological, and molecular characterization of pediatric invasive infections by Streptococcus pyogenes in Spain in a context of global outbreak. mSphere. 2024 Mar 26;9(3):e0072923. doi: 10.1128/msphere.00729-23. Epub 2024 Mar 5. PMID: 38440985 
Rodríguez-Villodres Á, Lepe-Balsalobre E, Ortiz De La Rosa JM, Giner Almaraz S, González De Herrero E, Cercenado E, García-Fernández S, Benito R, Ponz Mir R, Cantón R, Lepe JA. Activity of cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations on Enterobacter cloacae complex and Klebsiella aerogenes in Spain (SMART 2016-2022). JAC Antimicrob Resist. 2024 Jun 6;6(3):dlae087. doi: 10.1093/jacamr/dlae087. eCollection 2024 Jun. PMID: 38847006 
Lago-Rodriguez AE, Fraile-Ribot PA, Amengual-Antich I, Gual-Capllonch F, Garcia-Gasalla M. Q Fever Endocarditis: A Challenging Diagnosis in a Patient Referring Weight Loss and Anorexia, and With Granulomas in Gastric Biopsy Specimens. Clin Case Rep. 2024 Nov 29;12(12):e9635. doi: 10.1002/ccr3.9635. eCollection 2024 Dec. PMID: 39619303 
Gavalda M, Fullana MI, Ferre A, Peña RR, Armendariz J, Torrallardona O, Magraner A, Lorenzo A, García C, Mut G, Planas L, Iglesias C, Fraile-Ribot P, Macia Romero MD, Riera M, García-Gasalla M. Clinical Characteristics and Microorganisms Isolated in Community-Acquired Pneumonia in the COVID-19 Period. Can J Infect Dis Med Microbiol. 2024 Mar 19;2024:5948747. doi: 10.1155/2024/5948747. eCollection 2024. PMID: 38532828 
Vetter-Laracy S, Jimenez V, Roldán M, Bernardino M, Balliu-Badia P, Lara P, Arcay RM, Fraile-Ribot P, Vila M, Fanjul F. Neonatal SARS-CoV-2 immunoglobulin G antibodies at delivery and their impact on COVID-19. Eur J Clin Microbiol Infect Dis. 2024 Apr;43(4):693-702. doi: 10.1007/s10096-024-04773-3. Epub 2024 Feb 7. PMID: 38326544 
Navarro F, Oliver A, Larrosa MN; Spanish Antibiogram Committee (COESANT). Considerations to the comments on the recommendations of the Spanish Antibiogram Committee (COESANT) for the preparation of Cumulative Antibiotic Sensitivity Reports. Enferm Infecc Microbiol Clin (Engl Ed). 2024 Oct;42(8):465-466. doi: 10.1016/j.eimce.2024.05.006. Epub 2024 May 19. PMID: 38763864
Gijón D, García-Castillo J, Fernández-López MC, Bou G, Siller M, Calvo-Montes J, Pitart C, Vila J, Torno N, Gimeno C, Cruz H, Ramos H, Mulet X, Oliver A, Ruiz-Garbajosa P, Canton R. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal. Rev Esp Quimioter. 2024 Feb;37(1):69-77. doi: 10.37201/req/098.2023. Epub 2023 Oct 26. PMID: 37882320
González de Herrero E, Moreno V, Martín-Pena ML, Ruiz de Gopegui E. An unexpected cause of myopericarditis in an immunocompromised patient. Enferm Infecc Microbiol Clin (Engl Ed). 2024 Jun-Jul;42(6):331-332. doi: 10.1016/j.eimce.2024.04.003. Epub 2024 May 1. PMID: 38697869 
Reina J, Iturbe A, Viana-Ramírez J, Sbert G, Carrasco J, Dueñas J Comparative analysis of acute respiratory infections of viral etiology in children under 6 months with and without nirsevimab in the Balearic Islands (2022-2023 and 2023-2024). Enferm Infecc Microbiol Clin (Engl Ed). 2024 Oct 22:S2529-993X(24)00211-9. doi: 10.1016/j.eimce.2024.10.002. Online ahead of print. PMID: 3944323 
Reina J, Viana-Ramirez J.[Impact in the adult population of immunization with nirsevimab in children under 6 months of age against respiratory syncytial virus]. Rev Esp Quimioter. 2024 Dec;37(6):512-514. doi: 10.37201/req/049.2024. Epub 2024 Jul 16. PMID: 39010814 
Reina J, Iturbe A. Detection of Epstein-Barr virus in female genital ulcers. Rev Esp Quimioter. 2024 Aug;37(4):365-366. doi: 10.37201/req/005.2024. Epub 2024 May 21. PMID: 38770625
